Cargando…
Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells
CD38 is the major NAD(+)-hydrolyzing ecto-enzyme in most mammals. As a type II transmembrane protein, CD38 is also a promising target for the immunotherapy of multiple myeloma (MM). Nanobodies are single immunoglobulin variable domains from heavy chain antibodies that naturally occur in camelids. Us...
Autores principales: | Baum, Natalie, Eggers, Marie, Koenigsdorf, Julia, Menzel, Stephan, Hambach, Julia, Staehler, Tobias, Fliegert, Ralf, Kulow, Frederike, Adam, Gerhard, Haag, Friedrich, Bannas, Peter, Koch-Nolte, Friedrich |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446682/ https://www.ncbi.nlm.nih.gov/pubmed/34539634 http://dx.doi.org/10.3389/fimmu.2021.703574 |
Ejemplares similares
-
Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD(+) Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells
por: Baum, Natalie, et al.
Publicado: (2020) -
Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo
por: Fumey, William, et al.
Publicado: (2017) -
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells
por: Schütze, Kerstin, et al.
Publicado: (2018) -
Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
por: Schriewer, Levin, et al.
Publicado: (2020) -
Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells
por: Hambach, Julia, et al.
Publicado: (2022)